Acquisitions in Hainaut, Belgium

Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.

Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.

Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.